International Medical Case Reports Journal (Sep 2023)
Myocarditis Following Inactivated SARS-CoV-2 Vaccine (Vero Cell) in an Adult Female in Vietnam: A Case Report
Abstract
Hoa Tran,1 Vu Hoang Vu,1 Duc Tran,2 Quang Dang Duy Pham,2 Khang Duong Nguyen,2 Binh Quang Truong1 1Department of Internal Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam; 2Cardiovascular Center, University Medical Center Ho Chi Minh City, Ho Chi Minh City, VietnamCorrespondence: Quang Dang Duy Pham, Tel +84937134599, Email [email protected]: During the Coronavirus disease 2019 (COVID-19) pandemic, vaccination against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has proven to be an important measure to help control disease spread and improve patient outcome. There are four distinct vaccine categories: inactivated viral vaccines, messenger RNA (mRNA) vaccines, adenovirus vector–based vaccines, and adjuvanted protein vaccines. In 2021, increased cases of myocarditis and pericarditis were reported after mRNA and adenovirus vector–based COVID-19 vaccination. A similar reporting pattern has not been observed after receipt of inactivated virus vaccines. Here, we present a case of clinically suspected acute myocarditis in a 26-year-old female, occurring 11 days after the administration of Sinopharm Vero Cell, an inactivated virus COVID-19 vaccine. This event led to acute heart failure, with marked clinical resolution observed within 34 days.Keywords: COVID-19 vaccine-associated myocarditis, inactivated virus COVID-19 vaccine, Vero Cell, SARS-CoV-2
